Hepanova, Inc. is a clinical-stage global pharmaceutical company developing First-in-Class drug candidates for chronic liver diseases. The company was founded in 2014 in California and runs two state-of-the-art R&D Centers located in Gaithersburg, Maryland and Shanghai Zhangjiang Hi-Tech Park, China. Hepanova’s compelling pipelines include multiple R&D programs targeting at MASH (metabolic dysfunction-associated steatohepatitis, formerly known as NASH), liver fibrosis, and HCC (hepatocellular carcinoma). The First-in-Class MASH & liver fibrosis drug, HPN-01 is currently in U.S. Phase I clinical trial, showing promising early results. It is also the only MASH candidate targeting all major mechanisms – hepatic steatosis, inflammation, and fibrosis simultaneously, with strong efficacy data in all three conditions.

[M&A IN DISCUSSION] Cellicure, Inc. provides innovative cell-based immunotherapy technologies, customized treatment regimens and real-world solutions for the current unmet therapeutic needs created by cancer, autoimmune diseases, and chronic inflammatory diseases. Our multiple groundbreaking CAR-NK technology platforms break through the current major challenges and bottlenecks of cell therapy development and industrialization, bringing significant competitive advantages. Partnering with Memorial Sloan Kettering Cancer Center (MSKCC), Cellicure’s innovative T cell engineering technology – the nCAR-T system, significantly enhances T cell infiltration and survival in tumor microenvironment, thus achieving better efficacies in the treatment of both solid tumors and hematological malignancies.

Led a multidisciplinary team to conduct basic and translational research in liver diseases, including viral hepatitis, hepatic steatosis, fibrosis, and liver cancer.

Dr. T. Jake Liang Laboratory at the Liver Diseases Branch of the NIH

Genome-wide RNAi functional screens in chronic liver disease.

Conducted clinical research on HCV/HIV co-infection cohorts.

Clinical practice specializing in hepatology and infectious diseases in a leading teaching hospital in Shanghai.